OV-329 is under clinical development by Ovid Therapeutics and currently in Phase I for Infantile Spasm (West Syndrome). According to GlobalData, Phase I drugs for Infantile Spasm (West Syndrome) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OV-329’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OV-329 overview
Small molecule is under development for the treatment of resistant orphan epilepsy associated with tuberous sclerosis complex, focal seizures (partial seizure), status epilepticus, infantile spasms, drug addiction, acute and chronic seizures. The drug candidate is administered through oral and intravenous route. It acts by targeting GABA aminotransferase.
See Also:
Ovid Therapeutics overview
Ovid Therapeutics is a biopharmaceutical company that includes drug discovery and development for epilepsies and rare CNS disorders. The company’s product pipeline such as soticlestat, GV101, OV329 and OV350. Its pipeline treats dravet syndrome and lennox-gastaut syndrome (LGS), cerebral cavernous malformations, tuberous sclerosis complex, infantile spasms, resistant epilepsies and neuropathologies. Ovid Therapeutics carries out drug discovery and development. The company works in partnership with patients, clinicians and scientists, foundations, academic centers, regulatory agencies and Graviton Biosciences. Ovid Therapeutics is headquartered in New York, the US.
For a complete picture of OV-329’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
